CTT Pharma Q2 10-Q: Going Concern, $31 Cash, Two Material Weaknesses
CTTH sits 100% above its 52-week low of $0.024 on light trading volume (0.2× avg).
Summary
CTT Pharma's Q2 2026 10-Q reveals a going concern warning, $31 in cash, and two material weaknesses in internal controls, alongside plans to raise $500,000 for a manufacturing facility.
Key Events · Earnings and Guidance · CTTH
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern within one year, citing ongoing net losses, negative operating cash flow, and working capital deficits.
-
Cash Position Collapses
Cash fell to $31 as of June 30, 2026, from $15,359 at December 31, 2025, while net loss for the six months was $99,908.
-
Two Material Weaknesses
Disclosure controls were ineffective due to lack of written internal control documentation and insufficient segregation of duties within accounting functions.
-
Funding Plan for Manufacturing
Company intends to use approximately $500,000 from the ELOC or other financing to establish a manufacturing facility, with no assurance the funding will be obtained.
Analysis · CTTH · Life Sciences
CTT Pharmaceutical Holdings ended Q2 2026 with just $31 in cash, down from $15,359 at year-end, and management states substantial doubt about the company's ability to continue as a going concern. The company also disclosed two material weaknesses in internal controls — no written documentation of control policies and insufficient segregation of duties. Against that backdrop, CTT plans to raise roughly $500,000 through its ELOC or other financing to build a manufacturing facility, though no funding is assured. The subsequent events note adds a patent approval for a nicotine strip and an early-stage LOI with a European partner, but neither generates revenue today.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTTH was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.